Eric Van Cutsem Selected Research

Cetuximab (Erbitux)

1/2021	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
12/2020	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
10/2019	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
10/2019	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
12/2018	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
11/2018	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.
2/2017	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
1/2017	Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
6/2015	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
3/2015	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Van Cutsem Research Topics

Disease

120	Neoplasms (Cancer) 12/2022 - 07/2004
117	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 04/2002
42	Disease Progression 12/2022 - 01/2004
41	Adenocarcinoma 12/2022 - 08/2005
38	Stomach Neoplasms (Stomach Cancer) 01/2022 - 01/2002
29	Colonic Neoplasms (Colon Cancer) 11/2022 - 04/2002
29	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2007
20	Pancreatic Neoplasms (Pancreatic Cancer) 12/2022 - 03/2004
20	Neutropenia 10/2021 - 01/2004
19	Fatigue 01/2021 - 10/2008
16	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 01/2010
15	Rectal Neoplasms (Rectal Cancer) 01/2021 - 02/2005
14	Diarrhea 07/2022 - 01/2007
12	Hypertension (High Blood Pressure) 01/2019 - 09/2009
10	Microsatellite Instability 10/2022 - 09/2009
9	Stomatitis 01/2018 - 01/2004
8	Exanthema (Rash) 03/2015 - 10/2007
7	Thrombocytopenia (Thrombopenia) 10/2021 - 10/2008
7	Vomiting 01/2019 - 01/2007
7	Nausea 01/2017 - 01/2004
6	Anemia 01/2020 - 10/2008
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2019 - 01/2005
5	Carcinoma (Carcinomatosis) 10/2018 - 12/2004
5	Febrile Neutropenia 01/2017 - 01/2013
5	Carcinoid Tumor (Carcinoid) 12/2015 - 01/2004
3	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 04/2022 - 09/2011
3	Inflammation (Inflammations) 08/2021 - 01/2018
3	Cholangiocarcinoma 10/2020 - 01/2018
3	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 08/2010
3	Infections 01/2018 - 02/2011
3	Anorexia 01/2017 - 10/2008
3	Cachexia 01/2016 - 01/2005

Drug/Important Bio-Agent (IBA)

51	Fluorouracil (Carac)FDA LinkGeneric 08/2021 - 04/2002
34	ErbB Receptors (EGF Receptor)IBA 08/2021 - 07/2004
33	Irinotecan (Camptosar)FDA LinkGeneric 10/2022 - 04/2002
33	Cetuximab (Erbitux)FDA Link 01/2021 - 07/2004
32	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2022 - 04/2002
32	Leucovorin (Folinic Acid)FDA Link 01/2021 - 04/2002
28	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2004
28	Bevacizumab (Avastin)FDA Link 12/2020 - 12/2004
20	Gemcitabine FDA Link 10/2021 - 03/2004
20	Capecitabine (Xeloda)FDA Link 08/2021 - 04/2002
18	Pharmaceutical PreparationsIBA 04/2022 - 01/2002
18	Monoclonal AntibodiesIBA 01/2019 - 08/2005
17	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 01/2007
16	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 08/2005
16	Panitumumab (Vectibix)FDA Link 01/2020 - 01/2007
13	pembrolizumabIBA 01/2022 - 03/2019
10	RamucirumabIBA 10/2021 - 10/2014
10	trifluridine tipiracil drug combinationIBA 01/2021 - 05/2015
10	Biological ProductsIBA 01/2020 - 07/2006
10	Everolimus FDA Link 01/2018 - 01/2010
9	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 10/2014
9	Docetaxel (Taxotere)FDA Link 10/2022 - 01/2004
9	afliberceptIBA 01/2020 - 10/2012
9	regorafenibIBA 01/2019 - 01/2013
7	DNA (Deoxyribonucleic Acid)IBA 08/2015 - 04/2008
6	Peptide Receptors (Peptide Receptor)IBA 01/2022 - 01/2013
6	Radioisotopes (Radionuclides)IBA 01/2022 - 01/2013
6	Octreotide (Sandostatin)FDA LinkGeneric 12/2021 - 04/2010
6	PlatinumIBA 10/2021 - 04/2012
6	Trastuzumab (Herceptin)FDA Link 01/2021 - 08/2010
6	Angiogenesis InhibitorsIBA 01/2019 - 01/2011
6	XELOXIBA 11/2015 - 06/2004
5	LigandsIBA 01/2022 - 10/2009
5	thiamine triphosphorate (TTP)IBA 01/2022 - 06/2004
5	Somatostatin Receptors (Somatostatin Receptor)IBA 12/2021 - 12/2017
5	Sodium Glutamate (Accent)IBA 11/2021 - 07/2013
5	ParaffinIBA 04/2014 - 04/2007
5	Tyrosine Kinase InhibitorsIBA 10/2012 - 08/2005
4	NivolumabIBA 10/2022 - 10/2018
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2010
4	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 10/2020 - 01/2015
4	130-nm albumin-bound paclitaxelIBA 01/2020 - 10/2013
4	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 02/2013
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 03/2011
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2012 - 08/2005
4	AntibodiesIBA 12/2010 - 05/2007
3	napabucasinIBA 07/2022 - 04/2019
3	lutetium Lu 177 dotatateIBA 12/2021 - 12/2017
3	binimetinibIBA 01/2021 - 10/2019
3	Cell-Free Nucleic AcidsIBA 01/2021 - 08/2015
3	encorafenibIBA 01/2021 - 10/2019
3	RNA (Ribonucleic Acid)IBA 03/2020 - 01/2019
3	AcriflavineIBA 01/2020 - 02/2017
3	trametinibIBA 01/2020 - 02/2015
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 01/2018
3	taxaneIBA 01/2019 - 04/2012
3	velourIBA 01/2018 - 01/2014
3	Codon (Codons)IBA 03/2015 - 10/2010

Therapy/Procedure

100	Therapeutics 12/2022 - 04/2002
87	Drug Therapy (Chemotherapy) 10/2022 - 01/2002
13	Adjuvant Chemotherapy 11/2022 - 08/2004
8	Radiotherapy 08/2021 - 12/2004
7	Chemoradiotherapy 01/2020 - 01/2002
6	Neoadjuvant Therapy 01/2021 - 03/2004
4	Microspheres (Microsphere) 08/2020 - 08/2010
3	Colectomy 04/2022 - 09/2011
3	Radiofrequency Ablation 10/2017 - 02/2014
3	Combination Drug Therapy (Combination Chemotherapy) 01/2016 - 08/2005